NPPB and cerebral cavernous malformation: Biomarkers such as B-type natriuretic peptide (BNP) and troponins have shown promise in identifying subclinical cardiac involvement; however, given their relatively low specificity due to the large number of confounding factors that can contribute to troponin or BNP elevation, their role in CCM diagnosis is still limited [21].